文献速递特殊人群用药药物不良反应与药物警戒

美沙酮经胎盘暴露与新生儿阿片戒断综合征风险

Transplacental methadone exposure and risk of Neonatal Opioid Withdrawal Syndrome.
PubMed 文献 · Pharmacotherapy · 2023-08-23

本研究为单中心前瞻性研究,纳入11对接受美沙酮治疗至34周及以后的阿片依赖母婴。结果显示需要NOWS治疗组母体与脐带美沙酮浓度比值显著高于非治疗组(7.7±1.9 vs 3.5±1.6,p=0.003),提示该比值可能预测NOWS治疗需求。

要点

  • 母体与脐带美沙酮浓度比值在需NOWS治疗组显著更高(p=0.003)。
  • 脐带美沙酮浓度在非治疗组较高但差异无统计学意义。
  • EDDP浓度及比值在两组间无差异。

核心结论

  • 美沙酮经胎盘通透性可能影响宫内暴露,母体与脐带美沙酮浓度比值或可预测NOWS治疗需求。

研究设计与样本

  • 单中心前瞻性研究,纳入11对阿片依赖母婴,母亲在妊娠34周及以后接受美沙酮治疗。

主要发现

  • 11名婴儿中6名需要NOWS治疗。
  • 需治疗组母体美沙酮浓度为329.1±229.7 ng/mL,非治疗组为413.2±329.8 ng/mL。
  • 非治疗组脐带美沙酮浓度为120.0±88.6 ng/mL,需治疗组为40.9±24.4 ng/mL,差异无统计学意义。
  • 需治疗组母体与脐带美沙酮浓度比值为7.7±1.9,非治疗组为3.5±1.6,差异有统计学意义(p=0.003)。
  • 母体与脐带EDDP浓度及比值在两组间无差异。

临床怎么用

  • 对于妊娠期接受美沙酮治疗的阿片依赖母亲,可考虑检测母体与脐带血美沙酮浓度比值以评估新生儿NOWS治疗风险。

局限性

  • 样本量小(11对母婴),需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Neonatal opioid withdrawal syndrome (NOWS) is a condition that often occurs in neonates born to mothers who received methadone treatment for opioid use disorder during pregnancy. Early identification and treatment of infants at risk of NOWS may improve clinical outcomes. The purpose of this study was to evaluate whether maternal and umbilical cord plasma concentrations of methadone and its metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), could predict the need for NOWS treatment. DESIGN: Single-center prospective study. SETTING: University of Michigan Neonatal Intensive Care Unit. PATIENTS: The study included 11 opioid-dependent mother-infant dyads, where the mothers were treated with methadone at 34 weeks' gestation or later. INTERVENTION: Maternal and cord blood samples were collected from the study participants. MEASUREMENTS AND MAIN RESULTS: Maternal and cord plasma concentrations of methadone and EDDP were determined. Six out of the 11 infants required treatment for NOWS. Maternal methadone plasma concentrations were comparable between infants requiring and not requiring NOWS treatment (329.1 ± 229.7 ng/mL vs. 413.2 ± 329.8 ng/mL). However, the average cord plasma methadone concentration in infants who did not require NOWS treatment was 2.9-fold higher than in those who required the treatment (120.0 ± 88.6 ng/mL vs. 40.9 ± 24.4 ng/mL), although the difference was not statistically significant. The ratios of maternal-to-cord methadone plasma concentrations were significantly higher in patients who required treatment for NOWS compared with those who did not (7.7 ± 1.9 vs. 3.5 ± 1.6, p = 0.003). Maternal and cord plasma EDDP concentrations and the maternal-to-cord plasma EDDP concentration ratios did not differ between patients who required and did not require treatment for NOWS. CONCLUSIONS: The results suggest that methadone permeability across the blood-placental barrier may affect in utero exposure to methadone, and the maternal-to-cord methadone plasma concentration ratio could be a potential biomarker for predicting the need for NOWS treatment.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Bhatt-Mehta V, Jing X, Wang X, et al. Transplacental methadone exposure and risk of Neonatal Opioid Withdrawal Syndrome. Pharmacotherapy. 2023. PMID: 37574548. doi:10.1002/phar.2863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。